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ABSTRACT
In parallel with the inconsistency in observational studies and chemoprevention 
trials, the mechanisms by which selenium affects prostate cancer risk have not 
been elucidated. We conducted a randomized, placebo-controlled trial to examine 
the effects of a short-term intervention with selenium on gene expression in 
non-malignant prostate tissue. Twenty-three men received 300 µg selenium per 
day in the form of selenized yeast (n=12) or a placebo (n=11) during 5 weeks. 
Prostate biopsies collected from the transition zone before and after intervention 
were analysed for 15 participants (n=8 selenium, n=7 placebo). Pathway analyses 
revealed that the intervention with selenium was associated with down-regulated 
expression of genes involved in cellular migration, invasion, remodeling and immune 
responses. Specifically, expression of well-established epithelial markers, such as 
E-cadherin and epithelial cell adhesion molecule EPCAM, was up-regulated, while 
the mesenchymal markers vimentin and fibronectin were down-regulated after 
intervention with selenium. This implies an inhibitory effect of selenium on the 
epithelial-to-mesenchymal transition (EMT). Moreover, selenium was associated with 
down-regulated expression of genes involved in wound healing and inflammation; 
processes which are both related to EMT. In conclusion, our explorative data showed 
that selenium affected expression of genes implicated in EMT in the transition zone 
of the prostate.
INTRODUCTION
Based on early observational and intervention 
studies, it has been suggested that an adequate status or 
intake of selenium may protect against prostate cancer 
[1–4]. The Nutritional Prevention of Cancer (NPC) trial 
showed that 200 μg selenized yeast per day reduced the 
incidence of prostate cancer, and advanced prostate cancer 
in particular [2]. More recent studies, however, did not 
consistently confirm a protective effect of selenium for 
prostate cancer [5–8]. Results of the Selenium and Vitamin 
E Cancer Prevention (SELECT) trial demonstrated that 
supplements with 200 μg L-selenomethionine did not 
decrease the incidence of prostate cancer among men in 
the general population [6, 9]. For men with high toenail 
selenium levels, a slightly increased risk of high-grade 
prostate cancer was found after supplementation with 
selenium [7]. Similarly, in men at high risk for prostate 
cancer, 200-400 μg of selenized yeast per day was not 
effective for prostate cancer prevention [8].
The relatively high baseline selenium levels of the 
participants are often considered a plausible explanation 
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for the unanticipated findings of subsequent trials as 
compared to the early NPC trial [6, 10, 11]. Intake 
and status of selenium in most European countries are 
relatively low as compared to the USA [10, 12]. This 
supports further exploration of the role of selenium for 
prostate cancer prevention in these populations with 
marginal selenium status [11]. Rather than initiating 
another large intervention trial, we advocate to first gain 
further insight into the mechanisms underlying the role 
of selenium in cancer biology and other health related 
outcomes.
In parallel with the inconsistency in observational 
studies and chemoprevention trials, the mechanisms 
by which selenium may affect prostate cancer risk have 
not been elucidated. Supplementation with selenium 
resulted in increased levels of selenium in the prostate 
as shown in previous studies [13]. Furthermore, it was 
demonstrated that after supplementation with 200 μg 
L-selenomethionine per day differences exist in gene 
expression profiles in human prostate tissue as compared 
to a placebo group [14]. Whether these differences in gene 
expression underlie possible chemopreventive properties is 
not clear, because L-selenomethionine itself did not show 
preventive effects for prostate cancer in the SELECT trial 
[6]. Other forms of selenium, such as selenized yeast, have 
been shown to be effective for the prevention of prostate 
cancer in a subgroup of participants with a low baseline 
selenium status [1, 2], however, detailed information on 
the molecular effects in prostate tissue is lacking.
The aim of the current study was to obtain more 
insight into the molecular pathways affected by selenium 
in the prostate. Therefore, we examined whole-genome 
expression profiles in non-malignant prostate tissue 
before and after a 5-week intervention with selenized 
yeast in a randomized, placebo-controlled trial in The 
Netherlands. The collection of prostate tissue before and 
after intervention allowed us to compare changes in gene 
expression within individuals over time.
RESULTS
From June 2007 to October 2010, 281 men were 
assessed for their eligibility to participate in this study. Of 
these, 23 men were finally enrolled; 12 participants were 
randomized to the selenium group and 11 participants to 
the placebo group (Supplementary Figure 1). Baseline 
characteristics of the participants are presented in Table 1. 
The median duration of the intervention period was 35 
days (interquartile range (IQR): 31; 35). Compliance, as 
assessed by pill count and inspection of research diaries, 
ranged from 94% to 100%.
Levels of selenium
Baseline levels of serum (p=0.562) or toenail 
(p=0.449) selenium did not differ between the two 
groups (Table 1). As compared to baseline values, the 
serum selenium levels after intervention increased in the 
selenium group (median increase 1.44 µmol/L, IQR 0.66; 
1.92, p=0.004), but not in the placebo group (median 
increase 0.02 µmol/L, IQR -0.04; 0.18, p=0.314).
Microarray analyses
Good quality RNA from prostate biopsies from 
the transition zone without evidence of malignancy 
was available before and after the intervention for 15 
participants, resulting in a total of 30 microarrays used 
in this study (Supplementary Figure 1). After Robust 
Multichip Average (RMA) normalization and filtering, 
18,437 genes were considered expressed and were 
included in further analyses (Supplementary Figure 2). 
Comparisons between the selenium and placebo group 
showed that for 2765 genes pairwise expression changes 
(after intervention minus before intervention) differed 
(Limma p-value <0.05). Subsequent within-group 
comparisons of individual gene expression profiles before 
and after intervention revealed that of these 2765 genes, 
expression of 915 genes (524 down-regulated and 391 
up-regulated) was changed in the selenium group. In the 
placebo group expression changes were observed for 1380 
out of 2765 genes, of which 661 were down-regulated and 
719 up-regulated (Supplementary Table 1). At baseline, 
differences in gene expression exist between the selenium 
and placebo group (n=2624 genes with Limma p-value 
<0.05).
Biological pathway analyses
To obtain more insight into the role of the 
differentially expressed genes, pathway analyses were 
conducted. The top-5 regulated canonical pathways are 
presented for both the selenium and the placebo group in 
Figure 1. The intervention with selenium was associated 
with down-regulated expression of genes involved in 
signaling pathways related to inflammation, cellular 
immune response and cellular growth, proliferation 
and development. Opposite effects were observed in 
the placebo group with expression of genes involved in 
pathways related to cellular immune responses being up-
regulated.
A gene set enrichment analysis (GSEA) was 
performed to explore the consistency of our findings for 
the selenium supplementation. Gene sets enriched in the 
selenium group are visualized in Figure 2. Two main 
clusters of gene sets were identified and were classified 
as A) wound healing, cellular adhesion and extracellular 
matrix interactions and B) inflammation and immunity. 
All of the gene sets in these two clusters were considered 
‘negative’ which implies that genes in these gene-sets 
were down-regulated after the intervention with selenium. 
Furthermore, expression of genes involved in cellular 
adhesion, inflammation, extracellular matrix interactions 
and chemokine signaling was down-regulated after 
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Table 1: Characteristics of the participants at baseline and after the intervention with selenium or placebo
All
Participants who completed the 
intervention
Participants who were eligible 
for microarray analysis
Placebo Selenium Placebo Selenium
Sociodemographic
Number of participants 23 11 12 7 8
Age at start intervention 
(years) 67.5 (65.0-72.3) 69.5 (63.0-72.6) 67.1 (65.2-71.2) 65.6 (61.9-73.1) 68.4 (65.2-71.9)
Body mass index  
(kg/m2) 26.2 (24.2-28.1) 26.2 (24.7-28.5) 26.4 (23.8-28.0) 26.2 (24.7-28.5) 25.5 (23.5-27.8)
Smoking
 Current 4 (17%) 1 (9%) 3 (25%) - 1 (13%)
 Former 13 (57%) 6 (55%) 7 (67%) 5 (71%) 5 (63%)
 Never 6 (26%) 4 (36%) 2 (8%) 2 (29%) 2 (25%)
Use of dietary 
supplements (current) 7 (30%) 4 (36%) 3 (25%) 2 (29%) 2 (25%)
Clinical
Prediagnostic PSA 
levels (ng/mL) 8.0 (4.5-10.3) 7.7 (3.8-11.0) 9.4 (6.0-10.2) 4.0 (3.0-11.0) 9.6 (6.4-10.2)
Diagnosis
  No evidence of 
malignancy 1 (4%) - 1 (8%) - 1 (13%)
 HGPIN 5 (22%) 4 (36%) 1 (8%) 3 (43%) 1 (13%)
 Prostate cancer 17 (74%) 7 (64%) 10 (83%) 4 (57%) 6 (75%)
Gleason score at 
biopsya
 <7 10 (59%) 3 (43%) 7 (70%) 3 (75%) 5 (83%)
 ≥7 7 (41%) 4 (57%) 3 (30%) 1 (25%) 1 (17%)
Chronic inflammation 
at baselineb
 No inflammation 8 (35%) 3 (27%) 5 (42%) 2 (29%) 2 (25%)
  <10% of the study 
biopsy 13 (57%) 7 (64%) 6 (50%) 5 (71%) 5 (63%)
  10-50% of the study 
biopsy 1 (4%) - 1 (8%) - 1 (13%)
 Unknown 1 (4%) 1 (9%) - - -
Type of treatment / 
clinical follow-up
 Re-biopsy 9 (39%) 4 (36%) 5 (42%) 3 (43%) 4 (50%)
  Radical 
prostatectomy 6 (26%) 4 (36%) 2 (17%) 2 (29%) -
 Radiotherapy 8 (35%) 3 (27%) 5 (42%) 2 (29%) 4 (50%)
(Continued )
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Figure 1: The top-5 pathways, identified by IPA Canonical Pathway Analysis, which are most significantly regulated 
by the intervention with selenium (lower panel) or placebo (upper panel). The numbers behind the pathways indicate the 
number of genes that belong to that pathway and the numbers behind the bars represent the number of differentially expressed genes within 
that pathway (these genes had a p-value of <0.05 in the within- and between-group comparisons). Significance of the pathways, as assessed 
by the Fisher’s Exact test, is expressed by a (-log2) p-value.
All
Participants who completed the 
intervention
Participants who were eligible 
for microarray analysis
Placebo Selenium Placebo Selenium
Intervention
Duration of intervention 
period (days) 35 (31-35) 35 (34-35) 33 (28-35) 35 (34-35) 35 (32-35)
Time between 
collection of prostate 
tissue (days)
64 (35-98) 65 (36-98) 64 (33-96) 65 (36-112) 49 (32-96)
Selenium levels
Toenail selenium  
(mg/kg) at baseline 0.45 (0.37-0.50) 0.43 (0.37-0.48) 0.44 (0.37-0.48) 0.42 (0.37-0.60)
Serum selenium levels 
(μmol/L)
at baseline 1.06 (0.92-1.18) 1.00 (0.92-1.08)c 1.09 (1.04-1.18) 1.06 (0.93-1.17)
after intervention 1.11 (0.95-1.25)d 2.36 (1.74-2.98)
 
c,e 1.12 (0.98-1.23) 2.82 (2.30-3.04)f
Data presented as median (interquartile range) or numbers (%). Statistical tests were only performed for toenail and serum 
selenium levels.
aOnly for participants with prostate cancer,
bChronic inflammation in the prostate biopsies was defined as infiltration of mononuclear cells at the periglandular stroma. 
The extent of inflammation was classified as affected volume (%) of the study biopsy.
cOne participant from the selenium group was excluded, because data on serum selenium levels at baseline and after 
intervention were not available,
dOne participant in the placebo group was excluded, because sample collection after the intervention failed.
eStatistically significant if compared to baseline levels (p=0.004, Wilcoxon Signed Rank test).
fStatistically significant if compared to baseline levels (p=0.012, Wilcoxon Signed Rank test).
Abbreviations: HGPIN high-grade prostatic intraepithelial neoplasia, PSA prostate specific antigen.
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intervention with selenium. For the placebo group, gene 
sets referring to inflammation, infection, hemostasis and 
cellular adhesion were enriched and considered ‘positive’ 
after the intervention (data not presented), which again 
points towards the opposite effects on gene expression 
found after the intervention with selenium versus placebo.
Based on the IPA Upstream Regulator Analysis, 
we identified regulators that may have been responsible 
for the observed expression changes. Predicted upstream 
regulators were considered relevant if the z-score was 
below -2 or above 2 and if the p-value of overlap was 
<0.05. The top-5 (based on z-score) of the predicted 
activated and inhibited regulators is presented in Table 2. 
Transforming growth factor β1 (TGFB1) was identified 
as an upstream regulator predicted to be inhibited in 
the selenium group and activated in the placebo group 
(p-value of overlap 3.70E-06 and 4.35E-12, respectively).
Focusing on the network of TGFB1 and a selection 
of other predicted upstream regulators in the selenium 
group, i.e. the SAM pointed domain containing ETS 
transcription factor (SPDEF) and WNT1 inducible 
signaling pathway protein 2 (WISP2), showed some 
common targets that are directly or indirectly controlled 
by these regulators (Supplementary Figure 3). Vimentin 
(VIM), E-cadherin (CDH1), OB-cadherin (CDH11) 
and connective tissue growth factor (CTGF) are all 
considered to be regulated by TGFB1, SPDEF and WISP2. 
Interestingly, both TGFB1 as well as the down-stream 
genes CDH1, CDH11, VIM and CTGF are suggested to 
be involved in the epithelial-to-mesenchymal transition 
(EMT). EMT is a process characterized by the transition of 
an epithelial phenotype towards a mesenchymal phenotype 
and is implicated in embryogenesis, inflammation, wound 
healing, as well as cancer progression and metastasis.
Based on literature [15], we obtained an EMT-
core gene list of 130 genes that are implicated in EMT 
and cancer progression. Gene expression changes after 
intervention for all our participants were plotted amongst 
this EMT-core list (Figure 3). Overall, the intervention 
with selenium resulted in down-regulated expression 
of genes known to be up-regulated during EMT. More 
specifically, expression of the ‘mesenchymal markers’ FN1 
(fibronectin), VIM, and CDH11 was down-regulated, while 
‘epithelial markers’, such as CDH1, SDC1 (syndecan-1) 
Figure 2: Enrichment map of the Gene Set Enrichment Analysis (GSEA) reflecting the gene sets that are enriched after 
the intervention with selenium. The gene sets are presented according to clusters which were assigned a label based on their common 
function or annotation. The clusters are: A. wound healing, cellular adhesion and extracellular matrix interactions, B. inflammation and 
immunity, C. metabolism, D. muscle contraction, E. miscellaneous. Down-regulated gene sets are visualized as solid grey nodes, while up-
regulated gene sets are white nodes with a grey border. Size of the nodes represents the number of genes involved. If there are overlapping 
genes between gene sets, the gene sets are connected through a line.
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and EPCAM (epithelial cell adhesion molecule), were up-
regulated after intervention with selenium.
In order to explore the consistency and robustness 
of our findings, we correlated the selenium-induced 
expression changes of all statistically significant (in 
within-, and between-group comparisons) EMT-related 
genes amongst each other. The corresponding Pearson 
correlation matrix for selenium (Figure 4) showed that 
expression changes of genes that are known to be up-
regulated during EMT (i.e. mesenchymal markers) were 
inversely correlated to the expression changes of genes 
down-regulated during EMT (i.e. epithelial markers). A 
simplified hypothetical model for the suggested effects of 
selenium on EMT in the prostate is presented in Figure 5.
DISCUSSION
Our study demonstrated that a 5-week intervention 
with selenium was associated with changes in expression 
of genes implicated in EMT in non-malignant prostate 
tissue. EMT is characterized by the transition of an 
epithelial towards mesenchymal phenotype with its 
Table 2: The top-5 of the predicted activated and inhibited upstream regulators with the highest and lowest z-scores 
according to IPA Upstream Regulator Analysis
Fold change after 
intervention Molecule type
Predicted 
activation state Activation z-score p-value of overlap
Selenium
TNF -1.1 cytokine Inhibited -3.85 1.94E-03
PDGF BB NA complex Inhibited -2.56 3.39E-05
TP53 1.1 transcription regulator Inhibited -2.32 4.44E-03
TGFB1 -1.2 growth factor Inhibited -2.28 3.70E-06
STAT5a/b NA group Inhibited -2.24 1.93E-03
TAB1 -1.0 enzyme Activated 2.00 1.39E-02
SPDEF 1.4 transcription regulator Activated 2.16 3.97E-02
MAP3K7 -1.0 kinase Activated 2.22 1.02E-02
WISP2 -1.2 growth factor Activated 2.45 3.16E-03
Placebo
COL18A1 1.1 other Inhibited -3.77 1.94E-07
SPDEF -1.3 transcription regulator Inhibited -2.95 3.75E-04
NEUROG1 -1.0 enzyme Inhibited -2.83 3.85E-08
JAG2 1.1 complex Inhibited -2.45 1.30E-02
IL1RN 1.2 transcription regulator Inhibited -2.38 1.66E-03
IFNG NA cytokine Activated 4.89 1.03E-12
PDGF BB NA complex Activated 5.48 9.59E-20
TGFB1 1.3 growth factor Activated 5.70 4.35E-12
TGM2 1.8 enzyme Activated 6.10 2.79E-09
TNF 1.1 cytokine Activated 6.94 7.97E-29
For calculation of the z-score IPA included information about the up- or down-regulated status of the genes in the 
dataset. For this analysis, the expression of genes was considered up- or down-regulated if the p-value for the within 
(after intervention versus baseline) and between group (changes in selenium versus placebo) comparisons was below 
p<0.05. Upstream regulators in the top-5 of the highest and lowest z-scores are only presented if their p-value of overlap 
was below 0.05.
Abbreviations: IPA Ingenuity Pathway Analysis, NA not available
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Figure 3: Heatmap of the individual gene expression changes of 130 EMT-core genes in participants receiving 
selenium or placebo. According to literature [reference 15], panel A represent genes that are up-regulated during EMT, while panel 
B includes genes that are down-regulated during EMT. Changes in gene expression are presented as signal-log-ratios (green; SLR ≤ -0.5 
to red; SLR ≥ 0.5). For genes with bold names, the expression changed after the intervention with selenium (Limma p-value <0.05). 
Underlined genes had expression changes that are significantly different between the selenium and placebo group (Limma p-value <0.05). 
Abbreviations: EMT epithelial-to-mesenchymal transition, SLR Signal-Log-Ratio.
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accompanying properties such as the ability to migrate and 
invade [16, 17]. Based on our findings, we hypothesized 
that selenium may be able to prevent, inhibit or reverse the 
transition of the epithelial to the mesenchymal phenotype. 
Expression of numerous well-established epithelial cell 
markers was increased, while expression of mesenchymal 
markers was decreased after intervention with selenium. 
The observation that expression changes for epithelial 
versus mesenchymal markers were inversely correlated 
implies that our findings were consistent and were not 
likely resulting from chance findings.
EMT plays an important role during embryogenesis, 
inflammation and wound healing as cellular migration 
and invasion facilitates organ development, tissue 
(re)modelling and regeneration [17, 18]. In parallel with 
the reported expression changes for genes implicated in 
EMT, expression of genes involved in these processes was 
affected after the intervention with selenium as well. A 
possible, but speculative, explanation for the pronounced 
inflammatory gene expression profile observed in the 
placebo group may be a persisting inflammatory response 
resulting from the first series of prostate biopsies. 
Interestingly, this inflammatory expression profile 
was not observed in the selenium group, which points 
towards a possible anti-inflammatory effect of selenium 
in the prostate. It should be noted that the median, but 
not mean, time between the repeated collection of prostate 
biopsies tended to be slightly shorter for participants in 
the selenium versus placebo group. The time between the 
biopsies for the individual participants was [32, 32, 32, 35, 
63, 91, 98, 112 days] for the selenium group and [35, 36, 
63, 65, 72, 112, 112 days] for the placebo group, which did 
not reveal any systematic differences between the groups.
The intervention with selenium was also associated 
with expression changes of genes involved in wound 
healing, cellular adhesion and extracellular matrix 
interactions. Based on our GSEA results, we identified a 
cluster of gene sets related to wound healing which were 
down-regulated after the intervention with selenium. The 
pronounced effects hinting towards wound healing in the 
placebo group may again refer to repair and remodeling 
of prostate tissue resulting from the (repeated) biopsies. 
Interestingly, in the selenium group expression of genes 
involved in wound healing was down-regulated. Based 
Figure 4: Correlation matrix showing the correlations between the expression changes for genes involved in epithelial-
to-mesenchymal transition (EMT). Calculation of the Pearson correlation coefficient is based on the individual signal-log-ratios 
representing the expression changes after the intervention with selenium. Only genes from the EMT-core [15] list for which the expression 
changed after the intervention with selenium and differed from the placebo group (Limma p-value <0.05) are presented. Green legends 
besides the genes indicate that these genes are commonly down-regulated during EMT, while genes presented in red are commonly up-
regulated during EMT [15].
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upon these data, we carefully hypothesized that selenium 
may contribute to accelerated or improved wound healing 
in the prostate.
So far, the role of selenium in wound healing has not 
been extensively described. Few small clinical studies or 
animal experiments suggest that selenium may improve 
and accelerate wound healing under various conditions 
[19, 20]. One of the potential key players implicated in 
wound healing is the gap junction protein connexin43 
(Cx43) encoded by the GAJ1 gene [21]. Experimental 
down-regulation of Cx43 at wound sites resulted in an 
improved rate and quality of healing [22]. Our intervention 
with selenium was also associated with down-regulated 
expression of GAJ1/Cx43 as well as GJC1/Cx45, whereas 
in the placebo group the expression of these connexins 
did not change. Interestingly, increased expression of 
GAJ1/Cx43 has also been linked to metastatic behavior of 
prostate cancer cells [23, 24].
The potential mechanisms underlying the effect of 
selenium on EMT, with or without a direct relationship 
to wound healing and inflammation, have not been 
described in detail previously. It has consistently been 
shown that transforming growth factor β1 (TGFB1) is a 
major inducer of EMT [17, 25] and is also involved in 
inflammation and wound healing [18, 26]. In our study, 
the expression of TGFB1 is significantly down-regulated 
after the intervention with selenium, while up-regulated 
in the placebo group. TGFB1 was also one of the main 
predicted upstream transcriptional regulators. Changes in 
protein expression of TGFbeta in serum of elderly men 
after selenium supplementation have been previously 
described [27].
We also identified the sterile alpha motif (SAM) 
pointed domain-containing ETS transcription factor 
(SPDEF) as an upstream transcriptional regulator. SPDEF 
is highly expressed in normal prostatic epithelial tissue 
[28, 29]. Previous studies showed that SPDEF is required 
for CDH1 expression in prostate cancer cells [30] and 
that SPDEF is a downstream target of TGFB1 [31]. Our 
intervention with selenium was associated with increased 
SPDEF expression which is in line with the epithelial 
phenotype and the increase in CDH1 expression. In 
previous studies, it was consistently shown that SPDEF 
inhibits cancer cell migration in vitro [31, 32] as well as 
prostate cancer metastasis in vivo [33]. Loss of SPDEF 
was associated with occurrence of aggressive high-grade 
prostate cancer [32, 34]. Methylseleninic acid (MSA), a 
synthetic selenium compound, has been shown to induce 
Figure 5: Simplified hypothetical model for the suggested effects of selenium on epithelial-to-mesenchymal transition 
in prostate tissue. Abbreviations: EPCAM epithelial cell adhesion molecule, EMT epithelial-to-mesenchymal transition, MET 
mesenchymal-to-epithelial transition, SPDEF SAM pointed domain containing ETS transcription factor, TGFb transforming growth 
factor beta.
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expression of SPDEF in prostate cancer cells [34], which 
is in line with the findings of our study.
To the best of our knowledge, the direct role of 
selenium in the regulation of EMT and related processes 
in the prostate has not been described in detail before. 
From in vitro work, it is known that the effects of selenium 
on EMT-related gene expression as well as migratory 
capacity strongly depend on the selenium compound used, 
the experimental conditions and the cell types or tissues 
studied [35–40]. Data from human studies assessing the 
effects of selenium on gene expression profiles in prostate 
tissue are scarce. Tsavachidou and colleagues examined 
gene expression in distinct anatomical zones and cell 
types of the prostate after a 3-6 week intervention with 
L-selenomethionine [14]. Prostate tissue was collected 
at a single time point after the intervention period [14]. 
We collected prostate tissue before and after intervention, 
which allowed us to compare changes in gene expression 
within individuals. This aspect can be considered a major 
strength of our study, because variation due to inter-
individual differences did not hinder the interpretation 
of the microarray data. Furthermore, due to the repeated 
sample collection, we were able to detect changes in 
gene expression that may not be directly attributed to 
the intervention with selenium, such as responses to the 
biopsy or other clinical procedures.
The marginal baseline selenium status of the 
participants may also be considered a strength of our 
study. In the NPC trial, specifically the participants with 
relatively low selenium status at baseline (selenium 
<123.2 µg/L) seemed to benefit from the intervention 
with selenized yeast [2]. Baseline selenium levels of the 
participants of the SELECT trial were relatively high 
(median 135 µg/L) [6]. The median selenium level of 
our participants was 81 µg/L and increased to 185 µg/L 
after the intervention. Based on experimental studies in 
dogs and a number of observational studies in humans, 
a U-shaped dose response curve for selenium status and 
several health outcomes was suggested [10, 41, 42]. 
While overlaying the U-shaped dose response curve with 
our data, it seemed that our participants started with a 
‘low status’ and ended with an ‘optimal to high selenium 
status’. One should, however, carefully interpret these 
findings, since it is not possible to draw conclusions 
about beneficial health effects of selenium in the current 
setting. Furthermore, it should be mentioned that the 
optimal range of selenium intake and status is narrow 
and strongly depends on various factors such as intake of 
various selenium compounds [43], genotype [44, 45], and 
metabolic capacity [10].
A limitation of our study refers to the relatively 
small number of participants. Recruitment of participants 
was complicated inherent to the design of our study which 
required prostate sample collection at two consecutive 
time points and the unanticipated negative outcome of 
the SELECT trial. To what extent sample size affects the 
power to detect gene expression changes is difficult to 
assess for these data-driven expression profiling studies. 
At baseline, differences in gene expression exist between 
the selenium and placebo group (n=2624 genes), which 
may be attributable to unanticipated variation or outliers 
and the relatively small sample size. A subset of these 
genes was also differently expressed upon the intervention 
with selenium (n=437 genes, 17%). We cannot exclude 
the possibility that these baseline differences to some 
extent affected the responses observed. However, despite 
substantial variation and differences between the groups at 
baseline, gene expression changes were highly consistent 
within the groups after intervention. Furthermore, we 
examined effects of selenium supplementation at a 
transcriptional level and therefore we cannot rule out any 
potential post-transcriptional effects that may determine 
activity and functionality of other potential regulators, 
such as the selenoproteins.
For the current study, we collected non-malignant 
tissue from the transition zone of the prostate. 
Approximately 20% of the prostatic adenocarcinomas 
arise from this zone, in comparison to 70-80% from the 
peripheral zone [46]. The transition zone and the peripheral 
zones have been shown to differ in gene expression profiles 
[46], which may have consequences for the functional 
implications of our findings in other zones of the prostate. 
Limited amounts of tissue and common clinical practices 
precluded the assessment of selenium levels in the prostate 
or serum PSA levels after intervention, respectively. 
Other studies, however, have already shown that short-
term (2-6 weeks) supplementation with selenized yeast 
or L-selenomethionine resulted in increased levels of 
selenium in the prostate [13, 47, 48].
In conclusion, our explorative data imply that 
selenium is associated with the regulation of genes 
involved in cellular migration, invasion, tissue remodeling 
and the immune response in non-malignant tissue 
collected from the transition zone of the prostate. These 
processes are implicated in EMT and related events such 
as inflammation, wound healing and cancer progression. 
Taken altogether, these results suggest a preventive effect 
of selenium on prostate cancer progression rather than 
on prostate cancer development and future studies are 
warranted to confirm this hypothesis.
MATERIALS AND METHODS
Participants and design of the study
For this study, we collected non-malignant prostate 
tissue before and after a short-term intervention with 
selenized yeast or yeast placebo. We recruited participants 
from the Radboud university medical center, an academic 
tertiary referral center in Nijmegen, The Netherlands. Men 
scheduled for diagnostic prostate biopsies, and subsequent 
treatment with radical prostatectomy (RP) or radiotherapy 
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(RT) for prostate cancer, were invited for this study. Also, 
men scheduled for re-biopsies because of high-grade 
prostatic intraepithelial neoplasia (HGPIN) were eligible 
for inclusion. For practical and ethical reasons, the men 
included in this study were all at high risk for prostate 
cancer or diagnosed with prostate cancer, as collection 
of prostate tissue for the study had to be combined with 
standard invasive clinical procedures. However, for all 
participants only non-malignant prostate tissue, verified 
by histological examinations, was considered for the 
analyses.
Exclusion criteria were current use of dietary 
supplements providing more than the recommended daily 
allowance of 55 μg selenium per day, any malignancy in 
the preceding five years (except for non-melanoma skin 
cancer), current hepatic or renal disease or inflammatory 
bowel disease, and neo-adjuvant therapies for prostate 
cancer.
Overall, 23 participants were eligible for 
participation in the intervention study (Supplementary 
Figure 1). Before start of the intervention, prostate tissue, 
blood samples and toenail clippings were collected and 
body weight and height were measured. Furthermore, 
participants filled out a baseline questionnaire on 
sociodemographic characteristics, medical history and use 
of dietary supplements.
Intervention
Participants were randomly assigned using a 
permuted-block design (blocks of four participants) to 
take 300 μg selenium per day in the form of selenized 
yeast (SelenoPrecise®, Pharma Nord, Denmark) or a 
placebo (non-selenized yeast, Pharma Nord, Denmark). 
The non-selenized yeast tablets were based on yeast 
grown on selenium-deficient medium and smell, taste and 
appearance did not differ from the intervention tablets. 
Both intervention and placebo tablets were previously 
used in the PRECISE Trial pilot studies [49–51] and 
have been shown to have a stable batch-to-batch profile 
with L-selenomethionine (~81%) as the most abundant 
selenium compound in the intervention tablets [51, 52]. 
Compliance was assessed by checking research diaries, 
counting returned tablets and measuring serum selenium 
levels before and after intervention. The intervention 
period had an intended duration of five weeks and was 
depending on the time between enrollment and final 
treatment or re-biopsy. The intervention period of five 
weeks was chosen because this resembles the average 
time between diagnostic biopsies and treatment by RP. 
During the intervention period, participants were asked 
to take daily supplements with selenium or placebo. At 
the end of the intervention period, prostate tissue and 
blood samples were collected for 22 participants. Sample 
collection for one participant failed because of logistic 
reasons. All participants returned remaining pills and their 
completed research diaries in which details concerning the 
use of study supplements were registered. The institutional 
review board (CMO Regio Arnhem-Nijmegen) approved 
the design of the study and all participants provided 
written informed consent. The trial was registered at 
clinicaltrials.gov with identifier NCT00446901.
Selenium analyses
For serum selenium analyses, blood was collected 
into 10-ml serum tubes (Becton Dickinson B.V.). Serum 
was collected after centrifugation and stored at -20°C 
until analyses. Serum selenium levels were measured 
using an atomic absorption spectrometer (model 4100ZL, 
PerkinElmer) coupled with a graphite furnace and using 
Zeeman background correction [53]. The detection limit 
for this method was 0.10 μmol/L. For each analytical 
run, a series of standards (CertiPur® AAS standards, no. 
1197960100, Merck Chemicals, Germany) and a control 
(Pathonorm-HighTM, SERO AS, Norway) were included. 
All samples were analyzed in triplicate.
Baseline toenail selenium levels, indicative of a 
long-term selenium intake and status [54], were assessed 
using Instrumental Neutron Activation Analyses (INAA) at 
the Reactor Institute of Delft University, the Netherlands, 
as described previously [55].
Collection of prostate tissue
Prostate tissue was collected using an 18-gauge 
biopsy needle (Bard Biopsy Systems) during regular 10-
core prostate needle biopsy series guided by transrectal 
ultrasound (TRUS) or with a biopsy during RP. In both 
cases, the study biopsy was taken from the superior, 
ventral region of the left lobe of the prostate, which is 
specified as the transition zone. The study biopsy was 
directly embedded in Optimal Cutting Temperature 
(O.C.T.) Compound (Sakura Finetek Europe B.V.) and 
snapfrozen in liquid nitrogen. All samples were stored at 
-80°C.
Histology
The biopsies embedded in O.C.T. Compound were 
sectioned at -20°C. Representative sections of 5 μm were 
used for histological examinations; at least two sections 
were used for a Haematoxilin-Eosin (HE) staining. The 
remainder of the biopsy was sectioned at 20 μm and used 
for RNA extraction. All HE-stained slides were reviewed 
for malignancy, HGPIN and inflammation by an expert 
uropathologist.
RNA extraction
Total RNA was extracted from the sectioned 
prostate biopsies using TRIzol Reagent according to the 
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manufacturer’s instructions (Invitrogen). Isolated RNA 
was purified using RNeasy Micro columns (Qiagen). 
RNA integrity (RNA 6000 Nanochips for the Agilent 2100 
Bioanalyzer, Agilent Technologies) and total RNA yield 
(Nanodrop ND 1000, Nanodrop Products) were assessed 
for all samples. The mean RNA integrity (RIN) score 
was 8.2 (standard deviation: 0.66). Prostate biopsies with 
inadequate RNA yield (<20 ng/µl, n=1) or histological 
evidence of adenocarcinoma (n=6) were excluded, leaving 
biopsies of 15 participants available for microarray 
analyses (n=8 selenium, n=7 placebo) (Supplementary 
Figure 1).
Microarray analyses
A total of 30 RNA samples were processed for 
microarray analyses. Briefly, 100 ng of total RNA 
per sample was converted to cDNA, labeled using an 
Ambion WT Expression kit and hybridized to Affymetrix 
GeneChip Human Gene 1.0 ST Arrays. Probe sets were 
redefined according to Dai et al. [56] using the remapped 
chip description files (CDF) version 14.1.1 based on the 
Entrez Gene database. The normalized signal intensities 
were expressed as Robust Multichip Average (RMA) 
expression values [57]. Genes with RMA expression 
values >20 in at least 4 arrays were considered as 
expressed in prostate tissue and were selected for further 
analyses. Ratios of the log(base2) transformed intensity 
signals (signal-log-ratios, SLR) were used to compare 
the individual microarray data before and after the 
intervention. Changes in gene expression within each 
of the groups were considered statistically significant 
if the p-value derived from the linear model (Limma: 
Linear Models for Microarray Data) [58] with pairwise 
comparisons and empirical Bayesian correction was 
<0.05. Differentially changed genes between the two 
groups were also identified using the Limma models with 
Bayesian correction (Limma p-value <0.05). Microarray 
data are available from the Gene Expression Omnibus 
(GEO) repository with accession number GSE77959.
Biological pathway analyses
Regulated pathways were identified through the 
use of IPA (version 18030641, Ingenuity® Systems, 
www.ingenuity.com). For these analyses, expression 
of genes was considered up- or down-regulated if the 
p-value for the within- and between-group comparisons 
was <0.05. Canonical pathways with a p-value of <0.01 
in the Fisher’s exact test were considered as significant 
to the data. IPA Upstream Regulator Analysis was used 
to predict common regulators that may be responsible for 
the observed changes in gene expression. Prediction of 
regulators is based on two parameters; the z-score and the 
p-value of overlap. The z-score reflects the consistency of 
the gene expression patterns of the downstream genes in 
the dataset, whereas the p-value of overlap is calculated by 
a Fisher’s exact test for the overlap between the genes in a 
dataset (expected) and the genes actually regulated by the 
potential transcriptional regulator (observed).
In order to further explore the biological relevance 
and consistency of our findings, we also conducted 
Gene Set Enrichment Analyses (GSEA, http://www.
broadinstitute.org/gsea/index.jsp) [59] for the changes in 
gene expression after the intervention with either selenium 
or placebo. Cytoscape 2.8.2 [60] was used to visualize 
the GSEA results in an enrichment map [61]. Gene sets 
with a False Discovery Rate (FDR) q-value of <0.01 were 
considered enriched to the data.
Gitools software was used to construct a correlation 
matrice showing the Pearson correlation coefficients for 
the individual expression changes expressed as signal-log-
ratios of selected genes [62].
Statistical analysis
Since levels of selenium after intervention, duration 
of intervention and a number of other participants’ 
characteristics were not normally distributed, data were 
summarized as median and interquartile ranges or numbers 
and percentages. Baseline serum and toenail selenium 
levels were compared between the selenium group and 
the placebo group using the Mann-Whitney U test. Serum 
selenium levels after intervention were compared to 
baseline values using the Wilcoxon Signed Rank test. All 
statistical tests were two-sided and p-values below <0.05 
were considered as statistically significant. Statistical 
Package for Social Sciences (SPSS version 19, Chicago, 
Illinois) was used for all analyses unless otherwise stated.
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